[
    {
        "outcome_uid": "ec153cb0",
        "clinical_question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?",
        "population": "Patients with RA on oral MTX monotherapy 15 mg per week who are not at target",
        "intervention": "Increase the dose of oral MTX",
        "comparator": "Switch to SC MTX",
        "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 20)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "dd941abe"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to SC MTX": "43/46 (93.5%)",
                    "Increase dose of oral MTX": "36/46 (78.3%)"
                },
                "Annotation": {
                    "data": "1. SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n2. PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.19 (1.01 to 1.42)",
                    "Absolute Effect (95% CI)": "149 more per 1,000 (from 8 more to 329 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "213390a6",
        "clinical_question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?",
        "population": "Patients with RA on oral MTX monotherapy 15 mg per week who are not at target",
        "intervention": "Increase the dose of oral MTX",
        "comparator": "Switch to SC MTX",
        "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 50)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "dd941abe"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to SC MTX": "41/46 (89.1%)",
                    "Increase dose of oral MTX": "33/46 (71.7%)"
                },
                "Annotation": {
                    "data": "1. SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n2. PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.24 (1.01 to 1.53)",
                    "Absolute Effect (95% CI)": "172 more per 1,000 (from 7 more to 380 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "6758372e",
        "clinical_question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?",
        "population": "Patients with RA on oral MTX monotherapy 15 mg per week who are not at target",
        "intervention": "Increase the dose of oral MTX",
        "comparator": "Switch to SC MTX",
        "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 70)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "dd941abe"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to SC MTX": "5/46 (10.9%)",
                    "Increase dose of oral MTX": "4/46 (8.7%)"
                },
                "Annotation": {
                    "data": "1. SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n2. PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.25 (0.36 to 4.36)",
                    "Absolute Effect (95% CI)": "22 more per 1,000 (from 56 fewer to 292 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "166c79bb",
        "clinical_question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?",
        "population": "Patients with RA on oral MTX monotherapy 15 mg per week who are not at target",
        "intervention": "Increase the dose of oral MTX",
        "comparator": "Switch to SC MTX",
        "outcome": "Disability (follow up: 6 months; assessed with: HAQ)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "dd941abe"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to SC MTX": "46",
                    "Increase dose of oral MTX": "46"
                },
                "Annotation": {
                    "data": "1. SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n2. PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 2.3 lower (4.06 lower to 0.54 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "3379c301",
        "clinical_question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?",
        "population": "Patients with RA on oral MTX monotherapy 15 mg per week who are not at target",
        "intervention": "Increase the dose of oral MTX",
        "comparator": "Switch to SC MTX",
        "outcome": "Pain (follow up: 6 months; assessed with: VAS 0-10)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "dd941abe"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to SC MTX": "46",
                    "Increase dose of oral MTX": "46"
                },
                "Annotation": {
                    "data": "1. SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n2. PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 1.43 lower (2.05 lower to 0.81 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    }
]